The human gut microbiota is hailed as the ‘second genome’, and within it, the AKK bacterium stands as a ‘star strain’. Due to its close association with metabolic disorders such as obesity, diabetes, hyperlipidaemia, and fatty liver disease, it has become a focal point for research and development among global biopharmaceutical enterprises. However, the industrialisation of AKK has long been constrained by multiple technical bottlenecks: as a strict anaerobe, its cultivation demands stringent conditions and exhibits a prolonged growth cycle, making in vitro efficacy validation exceptionally challenging.
Since its inception, Muen Bio has consistently focused on developing live bacterial therapeutics and next-generation probiotics, assembling a research team comprising experts in microbiology, molecular biology, and clinical medicine. Addressing the industry-wide challenges in AKK research, the company has spent a decade overcoming these hurdles, establishing a comprehensive technological platform spanning resource discovery, functional research, engineering modification, application development, and scale-up production. This effort has resulted in the screening of 222 AKK strains, culminating in the successful isolation of a proprietary core strain: Akkermansia muciniphila AKM Lab-01®.
Leave a Reply
Your email is safe with us.